Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trofinetide for the Treatment of Girls and Women With Rett Syndrome in Japan
jRCT2031250113Active, not recruiting
- Sponsor
- Acadia Pharmaceuticals
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of trofinetide in Rett syndrome (RTT) (4 cohorts), sponsored by Acadia Pharmaceuticals. Primary endpoint: Clinical Global Impression-Improvement (CGI-I) Score at Week 12. Started Sep 2025; status: active, not recruiting.
02
Drugs
trofinetide
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on jRCT2031250113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250113.